PARSIPPANY, N.J., April 24, 2017 /PRNewswire/ -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (the "Company"), A fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday, April 26, 2017, at 1:30 p.m. Eastern time. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.   

RedChip's Global Online Growth Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change.

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests: PancraGEN®, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace's mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Contact:

Interpace Diagnostics
Investor Relations:

Paul Kuntz
RedChip Companies
Paul@Redchip.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/interpace-diagnostics-to-present-at-redchips-global-online-growth-conference-300444075.html

SOURCE Interpace Diagnostics Group, Inc.